NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...

LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...

Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...

Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...